Media coverage about Medifast (NYSE:MED) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medifast earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the specialty retailer an impact score of 46.2063383243975 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern’s scoring:
MED has been the subject of a number of recent analyst reports. ValuEngine lowered shares of Medifast from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. DA Davidson boosted their target price on shares of Medifast to $89.00 and gave the company a “buy” rating in a research note on Friday, December 8th. Zacks Investment Research lowered shares of Medifast from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Sidoti raised shares of Medifast from a “neutral” rating to a “buy” rating in a research note on Wednesday, March 7th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $86.67.
Shares of Medifast (NYSE:MED) opened at $89.85 on Friday. Medifast has a one year low of $40.00 and a one year high of $92.91. The firm has a market cap of $1,085.36, a PE ratio of 39.24, a P/E/G ratio of 1.87 and a beta of 0.61.
Medifast (NYSE:MED) last released its quarterly earnings data on Tuesday, March 6th. The specialty retailer reported $0.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.12. Medifast had a net margin of 9.19% and a return on equity of 26.39%. The company had revenue of $78.01 million during the quarter, compared to analyst estimates of $73.48 million. During the same period in the prior year, the firm earned $0.34 earnings per share. The firm’s revenue for the quarter was up 24.9% compared to the same quarter last year. analysts predict that Medifast will post 3.25 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 8th. Investors of record on Friday, March 30th will be paid a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 2.14%. The ex-dividend date of this dividend is Wednesday, March 28th. Medifast’s dividend payout ratio (DPR) is presently 83.84%.
In related news, Director Charles P. Connolly sold 8,000 shares of the company’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $90.95, for a total value of $727,600.00. Following the completion of the sale, the director now directly owns 45,342 shares of the company’s stock, valued at $4,123,854.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael C. Macdonald sold 20,000 shares of the company’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $84.45, for a total transaction of $1,689,000.00. Following the completion of the sale, the director now directly owns 334,188 shares of the company’s stock, valued at $28,222,176.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,500 shares of company stock valued at $3,086,425. 5.40% of the stock is owned by insiders.
WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Medifast (MED) Stock Price” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/23/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-medifast-med-stock-price.html.
Medifast Company Profile
Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.